What is it about?
This article describes the real-life experience of using new antiviral therapy to treat hepatitis C patients in Hong Kong. It supplements and supports the findings by large clinical trials in the West.
Featured Image
Why is it important?
Real-life experience reflects true patient profiles seen in the clinic everyday. Patients who are too complicated and difficult to manage will be excluded from clinical trials. This paper provides valuable data in Asian patients that are largely absent in the clinical trials, which are primarily conducted in America and Europe.
Perspectives
The efficacy and safety of the new antiviral drugs are largely the same in Chinese patients as in the West. More centres in Asia should look into the real-life results of these antiviral drugs in their countries. Governments in Asian countries should formulate national plans to eliminate hepatitis C with these new effective antiviral drugs.
Prof Henry LY Chan
Chinese University of Hong Kong
Read the Original
This page is a summary of: Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong, Journal of Gastroenterology and Hepatology, May 2017, Wiley,
DOI: 10.1111/jgh.13663.
You can read the full text:
Contributors
The following have contributed to this page
